Birchview Capital LP Has $567,000 Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Birchview Capital LP lowered its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 18.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,000 shares of the specialty pharmaceutical company’s stock after selling 15,000 shares during the period. Birchview Capital LP’s holdings in KalVista Pharmaceuticals were worth $567,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. SG Americas Securities LLC increased its stake in KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock valued at $123,000 after purchasing an additional 1,319 shares in the last quarter. Legal & General Group Plc raised its stake in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 1,494 shares during the period. JPMorgan Chase & Co. lifted its holdings in KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after acquiring an additional 1,670 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 2,043 shares during the period. Finally, AlphaQuest LLC increased its holdings in shares of KalVista Pharmaceuticals by 17.1% in the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company’s stock worth $150,000 after acquiring an additional 2,588 shares in the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 6,669 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the completion of the transaction, the chief executive officer now directly owns 287,811 shares in the company, valued at approximately $3,445,097.67. The trade was a 2.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par acquired 43,707 shares of the stock in a transaction on Thursday, January 30th. The shares were purchased at an average price of $8.76 per share, with a total value of $382,873.32. Following the completion of the transaction, the insider now owns 4,986,480 shares of the company’s stock, valued at approximately $43,681,564.80. This represents a 0.88 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 261,055 shares of company stock worth $2,397,646 and have sold 17,292 shares worth $184,625. 10.50% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Stock Up 0.9 %

Shares of KALV stock opened at $12.99 on Friday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50. The company has a market capitalization of $645.81 million, a PE ratio of -3.57 and a beta of 0.39. The firm has a 50 day moving average price of $11.61 and a two-hundred day moving average price of $10.36.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on KALV. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target for the company. Finally, Jones Trading reissued a “buy” rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).